Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis

Gupta, 1994, Antifungal agents: an overview, part II, J Am Acad Dermatol, 30, 911, 10.1016/S0190-9622(94)70112-1

Gupta, 1999, The new oral antifungal agents for onychomycosis of the toenails: a review, J Eur Acad Dermatol Venereol, 13, 1, 10.1111/j.1468-3083.1999.tb00837.x

Tosti, 1996, Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy, J Am Acad Dermatol, 34, 595, 10.1016/S0190-9622(96)80057-0

Alpsoy, 1996, Intermittent therapy with terbinafine for dermatophyte toe—onychomycosis: a new approach, J Dermatol, 23, 259, 10.1111/j.1346-8138.1996.tb04009.x

Gupta, 1997, Terbinafine—an update, J Am Acad Dermatol, 37, 979, 10.1016/S0190-9622(97)70076-8

Ryder, 1992, Terbinafine: mode of action and properties of the squalene epoxidase inhibition, Br J Dermatol, 126, 2, 10.1111/j.1365-2133.1992.tb00001.x

De Doncker, 1997, Itraconazole intermittent pulse therapy is effective and safe in the treatment of onychomycosis and dermatomycoses: an overview, J Am Acad Dermatol, 37, 969, 10.1016/S0190-9622(97)70074-4

Gupta, 1997, Current management of onychomycosis: an overview, Dermatol Clin, 15, 121, 10.1016/S0733-8635(05)70420-4

Cauwenbergh, 1988, Pharmacokinetic profile of orally administered itraconazole in human skin, J Am Acad Dermatol, 18, 263, 10.1016/S0190-9622(88)70037-7

Lynch, 1999, Multidrug therapy, Lepr Rev, 70, 70

Katoch, 1998, Is there a microbiological rationale for single-dose treatment of leprosy?, Lepr Rev, 69, 2

Schraufnagel, 1999, Tuberculosis treatment for the beginning of the next century, Int J Tuber Lung Dis, 3, 651

Wormser, 1979, Trimethoprim-sulfamethoxazole in the United States, Ann Intern Med, 91, 420, 10.7326/0003-4819-91-3-420

Barson, 1996, Successful therapy of Candida albicans arthritis with a sequential intravenous amphotericin B and oral fluconazole regimen, Pediatr Infect Dis J, 15, 1119, 10.1097/00006454-199612000-00013

Schaffner, 1993, Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism, Mycoses, 36, 421, 10.1111/j.1439-0507.1993.tb00732.x

Maesaki, 1994, Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus, Antimicrob Agents Chemother, 38, 2843, 10.1128/AAC.38.12.2843

De Cuyper, 1999, Therapeutic approach of recalcitrant toenail onychomycosis. Poster 347, Clinical Dermatology 2000, 119

Ryder, 1997, New findings on the in vitro activity of antifungal agents, 36

Gupta, 2000, A risk-benefit assessment of the newer oral antifungal agents to treat onychomycosis, Drug Safety, 22, 33, 10.2165/00002018-200022010-00004

Evans, 1999, Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis, BMJ, 318, 1031, 10.1136/bmj.318.7190.1031

De Backer, 1998, Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day, J Am Acad Dermatol, 38, S57, 10.1016/S0190-9622(98)70486-4

Kejda, 1999, Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis, Postgrad Med, 8, 12

Haneke, 1998, Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicenter trial, Mycoses, 41, 521, 10.1111/j.1439-0507.1998.tb00716.x

1999, 1

1996

Zehender, 1994, Elimination kinetics of terbinafine from human plasma and tissues following multiple-dose administration, and comparison with 3 main metabolites, Drug Invest, 8, 203, 10.1007/BF03258479

Schatz, 1995, A. Nail incorporation kinetics of terbinafine in onychomycosis patients, Clin Exp Dermatol, 20, 377, 10.1111/j.1365-2230.1995.tb01353.x